Mendelian randomisation is a technique which, fuelled by the results of GWA studies, can be used to determine causal relationships between intermediate phenotypes such as metabolite levels and outcomes such as cardiovascular disease . Much faster and cheaper than randomised controlled trials, and relatively free from the biases of observational studies, it has the potential to identify new drug targets and reduce attrition rates in the pharmaceutical development pipeline.